5 Short Squeeze Candidates To Watch This Week: Aterian, Harbor Custom Development Remain At The Top, Veru JoinsBenzinga • 05/02/22
FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 StudyGlobeNewsWire • 05/02/22
Veru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & InfectioGlobeNewsWire • 04/25/22
Why Veru May Be Set To Double, Triple In Price And How To Play This Consolidation PatternBenzinga • 04/12/22
Veru's Stock Nearly Triples As COVID-19 Drugs Cuts Reduces Deaths By 55% In Hospitalized PatientsBenzinga • 04/11/22
Veru's Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming EfficacyGlobeNewsWire • 04/11/22
Veru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer ConferenceGlobeNewsWire • 03/04/22
Veru to Present at the Oppenheimer 32nd Annual Healthcare Conference on March 15-17, 2022GlobeNewsWire • 03/01/22
Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers SymposiumGlobeNewsWire • 02/17/22
Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as PlannedGlobeNewsWire • 02/14/22
Veru Inc. (VERU) CEO Mitchell Steiner on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 02/09/22
Veru Reports First Quarter Fiscal 2022 Results as US FC2 Prescription Net Revenues Climb 27%GlobeNewsWire • 02/09/22